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Plasmacytoid DCs (pDCs) comprise one of two 
major subsets of human DCs. The myeloid sub-
set is characterized by the presence of CD11c, 
whereas pDCs correspond to a small subset of 
CD11c-negative circulating blood DCs (1). 
Human pDCs are CD4+ CD45RA+IL-3Rα+ 
(CD123) ILT3+ILT1− CD11c− lineage− cells 
(2). Two additional markers, BDCA-2 and 
BDCA-4 are expressed on human pDCs in pe-
ripheral blood and bone marrow (3).
In response to viral and bacterial stimuli, 
pDCs can mature and produce large amounts of 
type I IFNs (IFN-α/β) (4). Type I interferons 
activate NK cell cytolytic activity, but protect 
uninfected cells from NK cell–mediated lysis and 
aff  ect T cell function by inducing Th1 diff  eren-
tiation (5). Moreover, type I interferons promote 
diff   erentiation, maturation, and immuno-
stimulatory functions of DCs.
Recent fi  ndings suggest that pDCs play an im-
portant role in the balance of immune responses. 
Although resting pDCs may induce regulatory 
responses, their activated counterparts have a 
stimulatory capacity (6). In patients with ovarian 
carcinoma, resting pDCs present at the tumor 
site may help to maintain an immuno suppressive 
environment (7). Alternately, activated pDCs 
induce expansion of antigen-specifi  c memory 
CD8+ T cells and Th1 CD4+ T cell popula-
tions specifi   c for endogenous   antigens (8), 
infl  uenza virus (9, 10), and the MART-1/
melan A26-35 epitope (11). pDCs participate in 
innate immune responses against diff  erent types 
of viruses, eliciting a potent Th1 polarization. 
During infl  uenza viral infection, pDCs are able 
to prime virus-specifi  c primary and secondary 
CD4 and CD8 T cell immune responses in vitro 
and in vivo (12), but only when the pDCs are 
exposed to the replicative virus and not with 
nonreplicating, boiled, or ultraviolet-irradiated 
virus (9). This important observation suggests 
that intracellular virus protein expression is es-
sential for pDCs to present antigens in MHC 
class II. The poor capacity of freshly isolated 
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human and mouse pDCs to induce T cell pro  liferation is 
likely the result of their ineffi   cient capturing of antigens, in 
contrast with classical DCs (1).
In vivo, pDCs accumulate at sites of infl  ammation, sug-
gesting that pDCs contribute to the ongoing infl  ammatory 
response through the release of cytokines and chemokines 
and the activation of lymphocytes. Because of their capacity 
to secrete large amounts of type I interferons, it has been 
  suggested that pDCs induce maturation of local myeloid 
DCs, facilitating cross-priming of endocytosed targets (13). 
The ques  tion whether pDCs themselves can exploit antigen 
uptake receptors and present exogenous antigens has spurred 
the current study.
How pDCs might endocytose exogenous antigens is vir-
tually unknown. Uptake might occur via BDCA-2, a C-type 
lectin transmembrane glycoprotein (14) or via Fcγ receptors. 
pDCs express the low-affi   nity Fcγ receptor (CD32). More 
specifi  cally, pDCs express FcγRIIa (CD32a), but they lack 
FcγRIIb (CD32b) (15,16). FcγRIIa has been described as a 
potent immune-activating receptor and it contains an ITAM 
motif, capable of mediating phagocytosis, ADCC, and initia-
tion of infl  ammatory cytokine release (17).
Here, we show that human pDCs can indeed take up exog-
enous antigen through CD32/FcγRII and stimulate   antigen-
specifi  c CD4+ T cells.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Plasmacytoid DCs are able to take up exogenous antigen
pDCs can induce alloresponses (18), drive Th1 polarization 
(19), and are able to prime specifi  c CD4+ and CD8+ T cells 
when loaded with tumor peptides or upon viral infection 
(12). The previously reported poor ability of this subpopula-
tion of human DCs to generate primary specifi  c CD4+ T cell 
responses has been attributed to their apparent lack of an effi   -
cient machinery to internalize soluble proteins (2). Here, we 
investigated the capacity of highly purifi  ed pDCs (purity 
96.5 ± 1.8%, Fig. 1 A) to internalize KLH conjugated to the 
fl  uorescent dye Alexa Fluor 488 (Figs. 1 and 2). No internal-
ization of KLH was observed when pDCs were isolated from 
the blood of normal donors or of melanoma patients not vac-
cinated with KLH-loaded monocyte-derived DCs (Fig. 1 B). 
Surprisingly, we observed that KLH was effi   ciently taken up 
by freshly isolated pDCs from patients (n = 3; mean 45 ± 
13% positive cells; Fig. 1 B) who were vaccinated with KLH-
loaded monocyte-derived DCs. These patients all had high 
levels of specifi  c antibodies to KLH of the IgG isotype (Fig. 
1 C). In contrast, pDCs from patients (n = 2) vaccinated with 
KLH-loaded DCs, but who did not form IgG antibodies di-
rected against KLH, did not take up this protein (Fig. 2 A). 
This further supports the notion that uptake is dependent on 
the presence of KLH antibodies.
Figure 1.  Internalization of Alexa Fluor 488–labeled KLH by 
freshly isolated human pDCs and the presence of anti-KLH 
  antibodies in serum of vaccinated patients. (A) The scatter plot 
(side and forward scatter) of pDCs isolated by positive sorting using anti–
BDCA-4–conjugated magnetic microbeads is shown. Purity was checked 
by double staining using BDCA-2 (CD302) and IL-3 receptor (CD123). 
(B) pDCs were isolated from blood of normal donors, nonvaccinated 
  melanoma patients, and melanoma patients vaccinated with KLH-loaded 
monocyte-derived DCs. Only pDCs isolated from blood of vaccinated 
  patients who developed a humoral response against KLH were able to 
take up KLH (right), whereas pDCs isolated from healthy donors or before 
vaccination (left and middle) were not able to take up exogenous protein. 
(C) Total IgG antibodies specifi  c for KLH were measured by ELISA. (left) 
Serum   obtained from one patient before (●) and 2 mo after (■) the last 
inoculation of KLH-loaded monocyte-derived DCs. (right) The humoral 
response of individual patients after vaccination with KLH-loaded mono-
cyte-  derived DCs. Each square represents one patient (mean 1.7 ± 0.8). 
Data represent OD450 values.JEM VOL. 203, July 10, 2006  1631
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Antigen uptake is postvaccination serum dependent
The fi  ndings presented in Fig. 2 provide further evidence that 
only in the presence of serum-containing IgG directed against 
KLH (Fig. 2 B, black line) pDCs were able to take up the 
exogenous KLH in a serum concentration dependent way. 
In the presence of serum obtained from patients prevaccination 
(Fig. 2 B, dotted line) or serum from healthy donors (Fig. 2 A), 
KLH was not internalized. Internalization was confi  rmed by 
confocal microscopy imaging (Fig. 2 C and Fig. S1 (available at 
http://www.jem.org/cgi/content/full/jem.20052364/DC1) 
in which the fl  ow cytometric analysis of same sample is 
  depicted; the presence of KLH-Alexa inside the cell was 
clearly demonstrated by a z-scan series (Video 1, available at 
http://www.jem.org/cgi/content/full/jem.20052364/DC1).
A predominant role for antibody-mediated interna  lization 
of proteins is described for the IgG receptor CD32 (20). 
Here, we confi  rm previous data on the expression of CD32 
by pDCs (Fig. 3 A and Fig. S2, available at http://www.
jem.org/cgi/content/full/jem.20052364/DC1) (15,16). The 
uptake of KLH was inhibited when antibodies specifi  c for 
this receptor were added (Fig. 3 B). These data demonstrate 
that the uptake of KLH is mediated by antigen-specifi  c IgG 
anti  bodies binding to CD32. The fi  nding that pDCs freshly 
isolated from blood of vaccinated patients were able to in-
ternalize KLH without the addition of antibody-containing 
serum suggests the presence of antigen-specifi  c antibodies on 
the surface of circulating pDCs in vivo.
Fc receptors have previously been implicated in the up-
take of foreign particles and macromolecules by myeloid and 
monocyte-derived DCs, as such reducing the concentration 
of antigen required for T cell activation. After proper routing 
and processing, the uptake of antigens via Fc receptors by 
monocyte-derived DC not only results in CD4-mediated 
T cell responses but ultimately in cross-presentation of exog-
enous antigen to CD8+ T cells (20).
KLH is processed and presented to antigen-specifi  c T cells
Here, we show that KLH is taken up by pDCs via KLH-
  specifi  c antibodies binding to CD32. Fanger et al. was the 
fi  rst to show that circulating blood DCs can internalize an-
tigens via FcγRII (21). Recently, Means et al. showed that 
FcγRIIa is implicated in the pathogenesis of lupus   delivering 
exogenous immune complexes containing DNA to TLR9, 
revealing a novel signaling cascade in pDCs where a Fc 
  receptors and TLRs interact functionally (22). Here, we 
confi  rm their data by really showing complexes of KLH–
  Alexa inside the pDCs by confocal microscopy (Fig. 2 C 
and Video 1).   Furthermore, we extend their observations by 
showing that human pDCs not only take up immune com-
plexes via FcγRII but also effi   ciently  present  internalized 
Figure 2.  KLH uptake is dependent on the presence of anti-KLH 
antibodies. (A) Addition of serum from normal donors, melanoma patients 
before vaccination, and postvaccination serum from a patient who did not 
develop a humoral response to KLH did not mediate KLH uptake by pDCs. 
(B) pDCs from normal donors only take up KLH when incubated with serum 
containing antibodies against KLH (black line) (n = 12, mean 56 ± 16%) in 
a concentration-dependent manner. Serum from the same patient but 
now taken before vaccination and therefore negative for anti-KLH anti-
bodies did not facilitate KLH internalization (negative control, dotted line). 
(C) Confocal images clearly show that KLH (green) is taken up by pDCs 
(MHC class II membrane staining in red) in the presence of postvaccination 
serum (top) and not in the presence of prevaccination serum (bottom).1632  ANTIGEN PRESENTATION BY PLASMACYTOID DENDRITIC CELLS | Benitez-Ribas et al. 
  antigen to CD4+ T cells. We incubated PBLs from   patients 
with a cellular response to KLH with autologous pDCs 
pulsed with KLH. pDCs from patients who lacked a humoral 
response against KLH were not able to induce KLH-specifi  c 
proliferation (Fig. 4 A), corresponding to the lack of KLH 
uptake. This could not be attributed to the absence of specifi  c 
T cells because monocyte-derived DCs loaded with KLH ef-
fi  ciently induced a proliferative response (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20052364/DC1). 
In contrast, pDCs from patients with a positive humoral re-
sponse against KLH were able to induce a specifi  c proliferative 
response of PBLs (Fig. 4 B) and purifi  ed CD4+ T cells (Fig. 
4 C). Furthermore, we investigated whether pretreatment 
of pDCs with anti-CD32 mAb could also inhibit the KLH-
  specifi  c proliferation. In Fig. 5 A, it is shown that anti-CD32 
pretreatment with mAb signifi   cantly inhibits the specifi  c 
KLH proliferation. In accordance with the incomplete inhi-
bition by anti-CD32 mAb of the KLH uptake (Fig. 3 B), the 
proliferation was not completely abrogated (Fig. 5 A). These 
fi  ndings demonstrate that serum containing KLH-specifi  c Ab 
appeared essential for the uptake of KLH. To further substan-
tiate this fi  nding to KLH presentation by pDCs to T cells, 
we incubated pDCs with pre- and postvaccination serum. As 
depicted in Fig. 5 B, only pDCs incubated with postvaccina-
tion serum mediated PBLs and CD4 T cell proliferation and 
division in response to KLH (Fig. 5 B and Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20052364/DC1). 
These fi  ndings indicate the necessity of antigen-specifi  c anti-
bodies for uptake and presentation of exogenous antigens.
Collectively, our observations demonstrate that pDCs 
can take up, process, and present exogenous antigen, result-
ing in a memory T cell response. We propose that pDCs not 
only nonspecifi  cally support innate immunity by the secre-
tion of type I interferons but also support a secondary type of 
immune response. Based on the results shown in this study, 
pDCs may play a role in the presentation of exogenous anti-
gens, inducing a memory type of response.
In vivo the immunological outcome of pDC-mediated 
T cell stimulation will much depend on the activation state 
Figure 3.  KLH uptake is mediated by Fc𝗄RII/CD32. (A) Flow cyto-
metric analysis of FcγRII/CD32 surface expression on fresh pDCs (black 
line: FcγRII/CD32; dotted line: isotype control; n = 5 mean 67% ± 25). 
(B) The presence of anti-KLH antibody containing serum does facilitate 
the uptake of KLH (top left), but not of irrelevant protein (top right). This 
anti-KLH antibody–mediated uptake can be inhibited with anti-CD32 anti-
bodies (bottom right), but not by isotype control antibodies (bottom left).
Figure 4.  KLH-specifi  c T cell responses induced by KLH-loaded 
pDCs. pDCs were isolated from vaccinated patients with (right) or with-
out (left) an antibody response against KLH. pDCs were incubated over-
night in the absence (white bars) or presence (black bars) of KLH. pDCs 
were washed and cocultured at several ratios with PBLs (A–C) or purifi  ed 
CD4+ T cells (C) in X-VIVO 15 supplemented with 2% pooled human 
  serum. Freshly isolated pDCs were only able to induce a proliferative 
T cell response against KLH when anti-KLH antibodies were present in vivo 
(see Fig. 1 B for internalization). No increased proliferation was observed 
when irrelevant control protein was added (not depicted). Signifi  cant 
differences from control according to Student’s t test: *, P < 0.05; 
**, P < 0.001.JEM VOL. 203, July 10, 2006  1633
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of the pDC (6). Resting pDCs are thought to play an essen-
tial role in maintaining tolerance. In cancer patients, pDCs 
are found in the tumor tissue, but seem inactive despite the 
fact that circulating antibodies against tumor-associated pro-
teins may be present (7, 23). Although resting pDCs express 
FcγRII and can therefore internalize immune complexes, 
they express only low amounts of MHC class II and do not 
secrete signifi  cant amounts of type I interferons. These last 
characteristics might favor tolerance rather than induction 
of immunostimulatory T cell responses (6). Therefore, the 
balance between immunity and tolerance (24) will critically 
depend on the activation state of the pDC.
Recent studies have shown that pDCs may also accumulate 
in peripheral tissues during certain noninfectious infl  ammatory 
diseases, including autoimmune disorders such as psoriasis.
It has been indicated that pDCs initiate psoriasis through type I 
interferon production (25). Also, in systemic lupus erythema-
tosus (SLE), another autoimmune disorder, circulating pDCs 
are decreased, but large numbers of activated pDCs infi  ltrate 
the skin lesions actively producing type I interferon in these 
patients (26, 27). Immune complexes, consisting of pathogenic 
autoantibodies and DNA derived from apoptotic cells, stimu-
late pDCs to produce cytokines and chemokines via a cooper-
ative interaction between Toll-like receptor 9 and FcγRII 
(22, 28). Here, we hypothesize that the endogenous DNA-
containing autoantibody complexes found in serum of patients 
with SLE not only lead to type I IFN production but also 
could play a role in the adaptive immune response by stimulating 
autoantigen-specifi  c T cells in SLE patients.
Finally, our fi  nding that FcγRII may serve as an important 
antigen uptake receptor for pDCs may result in the develop-
ment of strategies to target antigens to pDCs in therapeutic 
settings. In autoimmune diseases, the role of pDCs is coming 
to the fore; for cancer or infectious diseases, antigen targeting 
to pDCs may prove a promising approach to modulate toler-
ance or immunostimulation.
MATERIALS AND METHODS
Cells. pDCs were purifi   ed from PBLs by positive isolation using anti–
BDCA-4–conjugated magnetic microbeads (Miltenyi Biotec) and adjusted to 
106 cells/ml in X-VIVO-15 (Cambrex) supplemented with 10 ng/ml IL-3.
Flow cytometry. CD32 staining and blocking were performed using anti-
CD32 (clone AT-10; Serotec), mouse isotype control IgG1, and as secondary 
mAb PE-conjugated goat anti–mouse. Mean fl  uorescence intensity and per-
centage of positive cells were determined by fl  ow cytometry.
Clinical vaccination protocol. PBLs and monocyte-derived DCs were 
isolated from melanoma patients participating in ongoing DC vaccination 
trials (29). The study was approved by the local regulatory committee and 
written informed consent was obtained from all patients. Antigen-pulsed 
monocyte-derived DCs (gp100 peptides, tyrosinase peptide and KLH) were 
administered intravenously and intradermally.
Humoral responses to KLH. Humoral responses to KLH were deter-
mined by ELISA (30).
KLH internalization assays. Endotoxin-free protein KLH was purchased 
from Calbiochem and control protein carcinogenic embryonic antigen was 
obtained from Abcam. Protein binding and internalization by pDCs was 
  assessed by direct labeling of protein with the Alexa Fluor 488 labeling 
kit (GE Healthcare). pDCs were incubated with 10 μg/ml Alexa-labeled 
Figure 5.  Role of anti-CD32 antibodies and anti-KLH antibody–
containing sera in pDC-induced T cell proliferation. (A) pDCs isolated 
from patients before vaccination were incubated with anti-KLH antibody–
containing serum in the presence of KLH. Anti-CD32 antibodies were 
added to investigate the role of this receptor. After overnight incubation, 
pDCs were washed and cocultured with PBLs (black bars) or CD4+ T cells 
(white bars) in X-VIVO 15 supplemented with 2% pooled human serum. 
Proliferation was measured after 48 h. For normalization, proliferation is 
depicted as relative proliferation. Maximum proliferation (T cell prolifera-
tion induced by KLH-loaded pDCs in the presence of isotype control anti-
body) of each experiment was set at 100 and relative proliferation (T cell 
proliferation induced by KLH-loaded pDCs in the presence of anti-CD32 
antibody) was calculated per experiment. In the presence of anti-CD32 
antibodies, a signifi  cant inhibition of the proliferation was observed 
 (Student’s  t test). (B) pDCs isolated from patients before vaccination 
were incubated with either postvaccination serum (containing anti-KLH 
antibodies) or prevaccination serum (no antibodies against KLH) in the 
  presence of KLH. After overnight incubation, pDCs were washed and 
  cocultured with PBLs (black bars) or CD4+ T cells (white bars) in X-VIVO 
15 supplemented with 2% pooled human serum. Proliferation was mea-
sured after 48 h. For normalization, proliferation is depicted as relative 
proliferation. Maximum proliferation (T cell proliferation induced by pDCs 
in the presence of postvaccination serum and KLH) of each experiment 
was set at 100 and relative proliferation (T cell proliferation induced by 
pDCs in the presence prevaccination serum and KLH) was calculated per 
experiment. Proliferation was predominantly observed in the presence of 
postvaccination serum (containing anti-KLH antibodies) and KLH. p-values 
indicate signifi  cant differences from maximum to Student’s t test.1634  ANTIGEN PRESENTATION BY PLASMACYTOID DENDRITIC CELLS | Benitez-Ribas et al. 
protein overnight at 37°C. Subsequently, cells were washed and analyzed by 
fl  ow cytometry.
Internalization of Alexa-labeled KLH was confi  rmed by confocal laser 
scanning microscopy. pDCs were incubated overnight with 10 μg/ml 
Alexa-labeled KLH in the presence of post- or prevaccination serum. Cells 
were fi  xed on poly-L-lysine coated glass slides, followed by staining with 
MHC class II mAb (clone Q5/13) or IgG2a isotype control as a secondary 
mAb goat anti–mouse Alexa 647 was used. Cells were imaged with a Bio-
Rad MRC 1024 confocal system operating on a Nikon Optiphot micro-
scope and a Nikon 60x planApo 1.4 oil immersion lens. Pictures were 
analyzed with Bio-Rad Lasersharp 2000 and Adobe Photoshop 7.0 (Adobe 
Systems) software.
Cellular responses to KLH. pDCs were washed and cocultured with 
KLH-responsive PBLs or purifi  ed CD4+ T cells at 37°C. pDCs were incu-
bated overnight with 5% pre- or postvaccination serum. Pretreatment with 
anti-CD32 antibody was performed for 20 min at 4°C followed by the over-
night incubation with the appropriate serum. After 2–4 d of coculture, a tri-
tiated thymidine incorporation assay was performed. Tritiated thymidine 
(1 μCi/well; MP Biomedicals) was added to the cell cultures and incorpora-
tion was measured after 16 h.
CFSE-labeled (1 μM) T cells. CFSE-labeled cells (105) were cultured 
with the indicated stimulus for 2 d, and subsequently, CFSE fl  uorescence 
  intensity was measured by fl  ow cytometry.
Statistics. All cultures were performed in triplicate and results are shown as 
the mean ± SD. Signifi  cant diff  erence from control according to Student’s 
t test.
Online supplemental material. Fig. S1 shows the fl  ow cytometric data 
concerning the uptake of KLH–Alexa of the same cells as used in Fig. 2 C. 
Fig. S2 shows CD32 expression by pDCs measured with diff  erent clones of 
antibodies recognizing CD32. Fig. S3 shows that the patients analyzed in 
Fig. 4 do have specifi  c T cells. Fig. S4 shows the comparison of T cell divi-
sion and T cell proliferation both induced by KLH-loaded pDCs. Video 1 
shows a z-scan analysis of pDCs stained with MHC class II antibodies (red) 
and internalized KLH–Alexa (green). Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20052364/DC1.
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